Submitted:
01 February 2025
Posted:
03 February 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Methods
2.1. Study Population and Study Procedures
2.2. Biological Sampling
2.3. Determination of Serum Prolidase Activity and Other Parameters
2.3. Statistical Analysis
3. Results
3.1. Demographic and Clinical Characteristics
3.2. Prolidase, Oxidative Stress, and Inflammatory Parameters
3. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| SPA | Serum prolidase activity |
| COPD | Chronic obstructive pulmonary diseases |
| SSc | Systemic sclerosis |
| AS | Ankylosing spondylitis |
| SSc – ILD | Scleroderma-associated interstitial lung disease |
| FEV1 | Forced expired volume |
| FVC | Forced vital capacity |
| PEF | Peak expiratory flow |
| PFT | Pulmonary function test |
| ROS | Reactive oxygen species |
| SOD | Superoxide dismutase |
| CAT | Catalase |
| GSH | Glutathione |
| GPx | Glutathione peroxidase |
| GR | Glutathione reductase |
| 8-OH-dG | 8-hydroxy-2-deoxyguanosine |
| TAC | Total antioxidant capacity |
| TOS | Total oxidant status |
| TAS | Total antioxidant status |
| IL-1α | Interleukin-1 alpha |
| IL-1β | Interleukin-1 beta |
| FGF | Fibroblast growth factor |
| TNF-α | Tumor necrosis factor alpha |
| IFN-γ | Interferon-gamma |
| PDGF | Trombosit kaynaklı büyüme faktörü |
| DLCO | Diffusion capacity of carbon monoxide |
| GTP | Guanosine triphosphate |
| ECM | Extracellular matrix |
References
- Leung, C.C.; Yu, I.T.; Chen, W. Silicosis. Lancet 2012, 379, 2008–2018. [Google Scholar] [CrossRef] [PubMed]
- Castranova, V.; Vallyathan, V. Silicosis and coal workers’ pneumoconiosis. Environmental Health Perspectives 2000, 108, 675–684. [Google Scholar] [CrossRef] [PubMed]
- Özcan, Ö.; Gültepe, M.; İpçioğlu, O.M.; Bolat, B.; Kayadibi, H. Prolidazın mutlak aktivitesini değerlendirmede fotometrik enzim aktivitesi ölçüm metodunun optimizasyonu. Türk Biyokimya Dergisi [Turkish Journal of Biochemistry–Turk J Biochem] 2007, 32, 12–16. [Google Scholar]
- Eni-Aganga, I.; Lanaghan, Z.M.; Balasubramaniam, M.; Dash, C.; Pandhare, J. Prolidase: A review from discovery to its role in health and disease. Frontiers in Molecular Biosciences 2021, 8, 723003. [Google Scholar] [CrossRef]
- Myara, I.; Myara, A.; Mangeot, M.; Fabre, M.; Charpentier, C.; Lemonnier, A. Plasma prolidase activity: A possible index of collagen catabolism in chronic liver disease. Clinical chemistry 1984, 30, 211–215. [Google Scholar] [CrossRef]
- Cakmak, A.; Zeyrek, D.; Atas, A.; Celik, H.; Aksoy, N.; Erel, O. Serum prolidase activity and oxidative status in patients with bronchial asthma. J Clin Lab Anal 2009, 23, 132–138. [Google Scholar] [CrossRef]
- Gencer, M.; Aksoy, N.; Dagli, E.C.; Uzer, E.; Aksoy, S.; Selek, S.; Celik, H.; Cakir, H. Prolidase activity dysregulation and its correlation with oxidative-antioxidative status in chronic obstructive pulmonary disease. J Clin Lab Anal 2011, 25, 8–13. [Google Scholar] [CrossRef]
- Ekin, S.; Arısoy, A.; Gunbatar, H.; Sertogullarindan, B.; Sunnetcioglu, A.; Sezen, H.; Asker, S.; Yıldız, H. The relationships among the levels of oxidative and antioxidative parameters, fev1 and prolidase activity in copd. Redox Rep 2017, 22, 74–77. [Google Scholar] [CrossRef]
- Gejyo, F.; Kishore, B.K.; Arakawa, M. Prolidase and prolinase activities in the erythrocytes of patients with chronic uremia. Nephron 1983, 35, 58–61. [Google Scholar] [CrossRef]
- Brosset, B.; Myara, I.; Fabre, M.; Lemonnier, A. Plasma prolidase and prolinase activity in alcoholic liver disease. Clin Chim Acta 1988, 175, 291–295. [Google Scholar] [CrossRef]
- ILO. Guidelines for the use of the ilo international classification of radiographs of pneumoconioses; International labour office: Geneva, 2000. [Google Scholar]
- Kitchener, R.L.; Grunden, A.M. Prolidase function in proline metabolism and its medical and biotechnological applications. J Appl Microbiol 2012, 113, 233–247. [Google Scholar] [CrossRef] [PubMed]
- Star, V.L.; Hochberg, M.C. Osteoporosis in patients with rheumatic diseases. Rheum Dis Clin North Am 1994, 20, 561–576. [Google Scholar] [CrossRef] [PubMed]
- Celik, A.; Birer, M.N.; Kilinc, M. Serum prolidase activity in systemic sclerosis. Clin Rheumatol 2017, 36, 1827–1832. [Google Scholar] [CrossRef] [PubMed]
- Jayson, M.I. Collagen changes in the pathogenesis of systemic sclerosis. Annals of the Rheumatic Diseases 1977, 36, 26. [Google Scholar] [CrossRef]
- Mock, W.L.; Green, P.C. Mechanism and inhibition of prolidase. J Biol Chem 1990, 265, 19606–19610. [Google Scholar] [CrossRef]
- Savas, E.; Aksoy, N.; Pehlivan, Y.; Sayiner, Z.A.; Oztürk, Z.A.; Tabur, S.; Orkmez, M.; Onat, A.M. Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien Klin Wochenschr 2014, 126, 341–346. [Google Scholar] [CrossRef]
- Baspinar, S.; Kırnap, M.; Baspınar, O.; Dizdar, O.S.; Kocer, D. Serum prolidase level in ankylosing spondylitis: Low serum levels as a new potential gold standard biomarker for disease activity. Rheumatol Int 2016, 36, 1609–1616. [Google Scholar] [CrossRef]
- Abraham, P.; Wilfred, G.; Ramakrishna, B. Plasma prolidase may be an index of liver fibrosis in the rat. Clin Chim Acta 2000, 295, 199–202. [Google Scholar] [CrossRef]
- Tarçin, O.; Gedik, N.; Karakoyun, B.; Tahan, V.; Sood, G.; Celikel, C.; Tözün, N. Serum prolidase and igf-1 as non-invasive markers of hepatic fibrosis during four different periods after bile-duct ligation in rats. Dig Dis Sci 2008, 53, 1938–1945. [Google Scholar] [CrossRef]
- Myara, I.; Miech, G.; Fabre, M.; Mangeot, M.; Lemonnier, A. Changes in prolinase and prolidase activity during ccl4 administration inducing liver cytolysis and fibrosis in rat. Br J Exp Pathol 1987, 68, 7–13. [Google Scholar]
- Horoz, M.; Aslan, M.; Bolukbas, F.F.; Bolukbas, C.; Nazligul, Y.; Celik, H.; Aksoy, N. Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis. J Clin Lab Anal 2010, 24, 207–211. [Google Scholar] [CrossRef] [PubMed]
- Kayadibi, H.; Gültepe, M.; Yasar, B.; Ince, A.T.; Ozcan, O.; Ipcioglu, O.M.; Kurdas, O.O.; Bolat, B.; Benek, Y.Z.; Guveli, H.; et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: A surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 2009, 54, 1764–1771. [Google Scholar] [CrossRef] [PubMed]
- Türkbeyler, I.; Demir, T.; Pehlivan, Y.; Kaplan, D.S.; Ceribasi, A.O.; Orkmez, M.; Aksoy, N.; Taysi, S.; Kisacik, B.; Onat, A.M. Prolidase could act as a diagnosis and treatment mediator in lung fibrosis. Inflammation 2012, 35, 1747–1752. [Google Scholar] [CrossRef] [PubMed]
- Zengin Doğu, D. The role of serum prolidase activity, mmp-1, mmp-7, tgf-β values in prediction of early fibrosis in patients with moderate and severe covid-19. Md. UnPublished: Selçuk University, (2023) 69. medical residency thesis.
- Oikonomidi, S.; Kostikas, K.; Tsilioni, I.; Tanou, K.; Gourgoulianis, K.I.; Kiropoulos, T.S. Matrix metalloproteinases in respiratory diseases: From pathogenesis to potential clinical implications. Curr Med Chem 2009, 16, 1214–1228. [Google Scholar] [CrossRef]
- Kaleli, S.; Akkaya, A.; Akdogan, M.; Gültekin, F. The effects of different treatments on prolidase and antioxidant enzyme activities in patients with bronchial asthma. Environ Toxicol Pharmacol 2006, 22, 35–39. [Google Scholar] [CrossRef]
- Yu, T.Y.; Pang, J.H.; Wu, K.P.; Chen, M.J.; Chen, C.H.; Tsai, W.C. Aging is associated with increased activities of matrix metalloproteinase-2 and -9 in tenocytes. BMC Musculoskelet Disord 2013, 14, 2. [Google Scholar] [CrossRef]
- Uysal, P.; Teksoz, D.; Aksan, H.; Durmus, S.; Uslu-Besli, L.; Cuhadaroglu, C.; Gelisgen, R.; Simsek, G.; Uzun, H. Relationship between serum sialic acid levels and prolidase activity with airflow obstruction in patients with copd. Medicine (Baltimore) 2022, 101. [Google Scholar] [CrossRef]
- Kurt, O.; Ergun, D.; Anlar, H.; Hazar, M.; Dilsiz, S.A.; Karatas, M.; Basaran, N. Evaluation of oxidative stress parameters and genotoxic effects in patients with work-related asthma and silicosis. Journal of occupational and environmental medicine 2023, 65, 146–151. [Google Scholar] [CrossRef]
- Anlar, H.G.; Bacanli, M.; İritaş, S.; Bal, C.; Kurt, T.; Tutkun, E.; Yilmaz, O.H.; Basaran, N. Effects of occupational silica exposure on oxidative stress and immune system parameters in ceramic workers in turkey. Journal of Toxicology and Environmental Health, Part A 2017, 80, 688–696. [Google Scholar] [CrossRef]
- Abdelatty, M.; Ebeid, M.; Salem, T. Epidemiological study on the effect of ceramic dust on egyptian worker health. Med. J. Cairo Univ 2014, 82, 169–175. [Google Scholar]
- Yildiz, A.; Demirbag, R.; Yilmaz, R.; Gur, M.; Altiparmak, I.H.; Akyol, S.; Aksoy, N.; Ocak, A.R.; Erel, O. The association of serum prolidase activity with the presence and severity of coronary artery disease. Coron Artery Dis 2008, 19, 319–325. [Google Scholar] [CrossRef] [PubMed]
- Gecit, I.; Aslan, M.; Gunes, M.; Pirincci, N.; Esen, R.; Demir, H.; Ceylan, K. Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 2012, 138, 739–743. [Google Scholar] [CrossRef] [PubMed]
- Kokacya, M.H.; Bahceci, B.; Bahceci, I.; Dilek, A.R.; Dokuyucu, R. Prolidase activity and oxidative stress in patients with major depressive disorder. Psychiatr Danub 2014, 26, 314–318. [Google Scholar] [PubMed]
- Ozbay, I.; Topuz, M.F.; Oghan, F.; Kocak, H.; Kucur, C. Serum prolidase, malondialdehyde and catalase levels for the evaluation of oxidative stress in patients with peripheral vertigo. Eur Arch Otorhinolaryngol 2021, 278, 3773–3776. [Google Scholar] [CrossRef]
- Kim, K.E.; Cho, D.; Park, H.J. Air pollution and skin diseases: Adverse effects of airborne particulate matter on various skin diseases. Life Sci 2016, 152, 126–134. [Google Scholar] [CrossRef]
- Piguet, P.F.; Collart, M.A.; Grau, G.E.; Sappino, A.P.; Vassalli, P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990, 344, 245–247. [Google Scholar] [CrossRef]
| Silicosis (n=113) | Silica exposed workers (n=70) | Healthy controls (n=53) | p-value | |
| Age (yr) | 41.61 ± 7.14a | 38.04 ± 7.12b | 41.66 ± 9.90 | .0043 |
| BMI (kg/m2) | 26.06 ± 3.66 | 26.01 ± 3.19 | 27.11 ± 3.68 | .1552 |
| Smoking status | <.0014 | |||
| Nonsmoker | 19 (16.8)a | 11 (15.7)a | 24 (45.3)b | |
| Smoker | 66 (58.4)a | 50 (71.4)a | 20 (37.7)b | |
| Exsmoker | 28 (24.8) | 9 (12.9) | 9 (17) | |
| Cigarette Pack-years | 13.50 (9.25 – 20) | 12 (8 – 19) | 12 (10 – 16) | .6101 |
| Total of work time (yr) | 15 (10 – 19) | 9 (5 – 16.75) | - | .0046 |
| Total of work time | .0034 | |||
| 1–5 yr | 13 (11.5)a | 19 (27.1)b | - | |
| 6–10 yr | 18 (15.9) | 19 (27.1) | - | |
| 11–15 yr | 33 (29.2) | 13 (18.6) | - | |
| >15 yr | 49 (43.4)a | 19 (27.1)b | - | |
| Working hours per day (hours/day) | 8.14 ± 1.18 | 8.02 ± 0.48 | - | .1246 |
| Use of masks | .1734 | |||
| Never | 18 (15.9) | 6 (8.6) | - | |
| Rarely | 8 (7.1) | 8 (11.4) | - | |
| Often | 42 (37.2) | 20 (28.6) | - | |
| Always | 45 (39.8) | 36 (51.4) | - | |
| FEV1 (% pred) | 90.41 ± 17.70 a | 92.36 ± 13.47a | 102.60 ± 10.55b | <.0013 |
| FVC (% pred) | 90.74 ± 15.92a | 92 ± 11.11a | 100.68 ± 12.21b | <.0012 |
| FEV1/FVC | 81.83 ± 6.70 | 83.36 ± 5.71 | 83.90 ± 4.72 | .0942 |
| PEF (% pred) | 84.18 ± 21.21 | 80.77 ± 20.95 | 88.15 ± 15.55 | .4602 |
| DLCO (% pred) | 99.01 ± 19.81 | 105.18 ± 19.34 | - | .7035 |
| ILO profusion score | 6 (5 – 9)a | 1 (1 – 1)b | 1 (1 – 1)b | <.0011 |
| ILO classification | ||||
| Category 0 | - | 70(100) | 53(100) | |
| Category 1 | 61 (54) | - | - | |
| Category 2 | 31 (27.4) | - | - | |
| Category 3 | 21 (18.6) | - | - | |
| Large opacity | - | - | ||
| A | 13 (11.5) | - | - | |
| B | 3 (2.7) | - | - | |
| C | 3 (2.7) | - | - |
| Silicosis (n=113) |
Silica exposed workers (n=70) |
Healthy controls (n=53) |
p-value | |
| Prolidase (ng/mL) | 0.38 (0.28 – 0.46) | 0.36 (0.30 – 0.43) | 0.35 (0.28 – 0.43) | .5581 |
| SOD (U/mL) | 0.04 (0.03 – 0.04)a | 0.04 (0.03 – 0.04)a | 2.02 (2.01 – 2.03)b | <.0011 |
| GPx (nmol/min/mL) | 4.52 (3.65 – 5.65)a | 4.34 (3.49 – 4.78)a | 6.22 (5.44 – 6.43)b | <.0011 |
| GR(nmol/mL/min) (×103) | 0.004 (0.003 – 0.010) | 0.004 (0.003 – 0.010) | 0.004 (0.002 – 0.005) | .1511 |
| CAT (U/mL) | 1.09 (0.53 – 1.61) | 0.94 (0.56 – 1.41) | 1.27 (0.65 – 1.51) | .2181 |
| 8-OH-dG (pg/mL) | 2640 (1780 – 3805)a | 2322.50 (1820 – 3037.50)a | 1575 (1255 – 1805)b | <.0011 |
| TNF-α (pg/mL) | 119.70 (109.70 – 219.70)a | 119.70 (111.95 – 216.90)a | 101.70 (90.70 – 108.70)b | <.0011 |
| FGF (pg/mL) | 350 (275.56 – 445.56)a | 405.56 (291.11 – 551.94)a | 271.11 (165.56 – 462.22)b | <.0011 |
| IFN-γ (pg/mL) | 776.63 (704.54 – 830.79)a | 772.04 (667.35 – 854.13)a | 617.46 (513.71 – 687.88)b | <.0011 |
| IL-1β (pg/mL) | 261.42 ± 82.88 | 259.42 ± 92.48 | 250.56 ± 97.35 | .7602 |
| IL-1α (pg/mL) | 71.48 ± 6.23a | 75.67 ± 5.87b | 63.65 ± 6.43c | <.0012 |
| Simple Silicosis (n= 94) |
Complicated Silicosis (n=19) | p-value | |
| Prolidase (ng/mL) | 0.38 (0.30 – 0.45) | 0.40 (0.22 – 0.51) | .9571 |
| SOD (U/mL) | 0.04 (0.02 – 0.04) | 0.04 (0.03 – 0.04) | .1491 |
| GPx (nmol/min/mL) | 4.51 (3.63 – 5.60) | 5.65 (4.40 – 6.03) | .0431 |
| GR(nmol/mL/min) (×103) | 0.004 (0.003 – 0.010) | 0.005 (0.003 – 0.010) | .3841 |
| CAT (U/mL) | 1.09 (0.84 – 1.60) | 0.82 (0.26 – 1.50) | .2801 |
| 8-OH-dG (pg/mL) | 2627.50 (1800 – 4295) | 2680 (1422.50 – 3245) | .2911 |
| TNF-α (pg/mL) | 120.70 (110.70 – 232.70) | 118.70 (108.70 – 142.20) | .2221 |
| FGF (pg/mL) | 350 (264.44 – 442.49) | 403.33 (324.44 – 466.11) | .3271 |
| IFN-γ (pg/mL) | 783.71 (700.79 – 830.79) | 737.04 (707.46 – 828.71) | .3491 |
| IL-1β (pg/mL) | 263.80 ± 84.16 | 249.65 ± 77.23 | .5002 |
| IL-1α (pg/mL) | 71.46 ± 6.42 | 71.55 ± 5.35 | .9542 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
